Bladder Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The report covers Global Bladder Cancer Therapeutics and Diagnostics Market Growth & Trends and it is Segmented by Product (Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics), and Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics)), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types), and Geography (North America, Europe, Asia- Pacific, Middle East and Africa and South America). The report offers the value (in USD million) for the abovementioned segments.

Bladder Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Bladder Cancer Therapeutics and Diagnostics Market Size

Bladder Cancer Therapeutics Diagnostics Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 4.00 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Bladder Cancer Therapeutics Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Bladder Cancer Therapeutics and Diagnostics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Bladder Cancer Therapeutics and Diagnostics Market Analysis

The Global Bladder Cancer Therapeutics and Diagnostics Market is expected to register a CAGR of 4% during the forecast period.

COVID-19 had a significant impact on the growth of the studied market. For instance, according to the study published in June 2022, titled "The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands" the number of BC diagnoses fell by 14% during the first COVID wave but rose back to pre-COVID levels by the end of 2020 (600 diagnoses a month). Treatment-related alterations were kept to a minimum and adhered to the revised guidelines. During the first wave, the surgical volume was not compromised. Overall, the impact of the initial COVID-19 outbreak on bladder cancer care in the Netherlands appears to be less severe than that documented for other solid tumors in the Netherlands and elsewhere. Additionally, as per the updates from American Urological Association's May 2022, during the peak of the COVID-19 pandemic in 2020, more than a quarter of patients with bladder cancer experienced care delays in the United States. 76,984 (27.2%) patients reported that their treatment was changed, delayed, or canceled as a result of the pandemic, including bladder cancer (27.5%). As a result of the pandemic, the market for bladder cancer therapeutics and diagnostics had been significantly impacted.

The bladder cancer therapeutics and diagnostics market may witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing healthcare expenditure and the growing burden of bladder cancer. For instance, in March 2022, the 'Don't Go Red' theme for Bladder Cancer Awareness has been declared by World Bladder Cancer Patient Coalition to raise awareness of warning signs and symptoms, as early detection is critical for enhancing long-term survival and quality of life. Such initiatives are expected to boost market growth over the forecast period.

Additionally, the increasing prevalence of bladder cancer across the world supports the market expansion over the forest period. For Instance, the Global Cancer Observatory Statistics 2020 reported that bladder cancer and prostate cancer are among the top 10 high incidence cancer around the world. The same source also reported that in 2020, the estimated number of new cases of bladder cancer was 573,278, and that of prostate cancer was 1,414,259 cases among both sexes in the year 2020. Such a high incidence of cancer worldwide is propelling the market over time.

Additionally, various strategies adopted by the key market players, such as product launches and mergers and acquisitions, are anticipated to drive the market over the forecast period. For Instance, in August 2021, Merck, known as MSD outside of the United States and Canada, reported a label update for KEYTRUDA, Merck's anti-PD-1 treatment, in first-line advanced urothelial carcinoma (bladder cancer) in the United States.

Thus, all aforementioned factors are expected to boost the market growth. However, the rise in the number of patent expiration and increased use of the generic drug may restrain the market growth.

Bladder Cancer Therapeutics and Diagnostics Industry Overview

The bladder cancer and therapeutics and diagnostics market is moderately competitive and consists of several major players. The major companies active in the market are AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche Ltd, Novartis, and Pfizer. The companies present in the market are focusing on product innovations, expansions, finding new markets, or innovating their core competencies, in order to expand their market shares.

Bladder Cancer Therapeutics and Diagnostics Market Leaders

  1. Bristol-Myers Squibb Company

  2. GlaxoSmithKline PLC

  3. Johnson & Johnson (Janssen Pharmaceutical)

  4. F. Hoffmann-La Roche

  5. Merck & Co. Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Bladder Cancer Therapeutics Diagnostics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Bladder Cancer Therapeutics and Diagnostics Market News

  • In July 2022, The United States Food and Drug Administration (FDA) agreed to review ImmunityBio's Biologics License Application (BLA) for N-803 in patients with or without Ta or T1 illness who have non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).
  • In July 2022, Nanostics Inc., launched a prospective clinical study designed to validate a novel and minimally invasive bladder cancer diagnostic test, ClarityDX Bladder, using its ClarityDX diagnostic platform. In partnership with the University of Alberta's Alberta Prostate Cancer Research Initiative (APCaRI) and DynaLIFE Medical Labs

Bladder Cancer Therapeutics and Diagnostics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Awareness on Bladder Diseases and Available Therapies
    • 4.2.2 Increasing Healthcare Expenditure
    • 4.2.3 Increasing Burden of Bladder Cancer
  • 4.3 Market Restraints
    • 4.3.1 Rise in the Number of Patent Expiration and Increased Use of Generic Drugs
    • 4.3.2 Asymptomatic Nature of the Disease
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - in USD million)

  • 5.1 By Product
    • 5.1.1 Therapeutics
    • 5.1.1.1 Chemotherapy
    • 5.1.1.2 Immunotherapy
    • 5.1.1.3 Other Therapeuticss
    • 5.1.2 Diagnostics
    • 5.1.2.1 Cystoscopy
    • 5.1.2.2 Bladder Ultrasound
    • 5.1.2.3 Urinalysis
    • 5.1.2.4 Other Diagnostics
  • 5.2 By Cancer Type
    • 5.2.1 Transitional Cell Bladder Cancer
    • 5.2.2 Squamous Cell Bladder Cancer
    • 5.2.3 Other Cancer Types
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Ameritech Diagnostic Reagent(Jiaxing)Co., Ltd
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Novartis International AG
    • 6.1.7 Pfizer Inc.
    • 6.1.8 Abbott Inc.
    • 6.1.9 Endo Pharmaceuticals Inc.
    • 6.1.10 Johnson & Johnson (Janssen Pharmaceutical)
    • 6.1.11 Merck & Co. Inc
    • 6.1.12 Astellas Pharma Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Bladder Cancer Therapeutics and Diagnostics Industry Segmentation

As per the scope of the report, bladder cancer is a tumor that starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. Several therapies have been developed to treat bladder cancers, which, in turn, build a high demand for the bladder cancer therapeutics market. The Bladder Cancer Therapeutics and Diagnostics Market is segmented by Product (Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics), and Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types), and Geography (North America, Europe, Asia- Pacific, Middle East and Africa and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the abovementioned segments.

By Product Therapeutics Chemotherapy
Immunotherapy
Other Therapeuticss
Diagnostics Cystoscopy
Bladder Ultrasound
Urinalysis
Other Diagnostics
By Cancer Type Transitional Cell Bladder Cancer
Squamous Cell Bladder Cancer
Other Cancer Types
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Bladder Cancer Therapeutics and Diagnostics Market Research FAQs

What is the current Global Bladder Cancer Therapeutics and Diagnostics Market size?

The Global Bladder Cancer Therapeutics and Diagnostics Market is projected to register a CAGR of 4% during the forecast period (2025-2030)

Who are the key players in Global Bladder Cancer Therapeutics and Diagnostics Market?

Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Johnson & Johnson (Janssen Pharmaceutical), F. Hoffmann-La Roche and Merck & Co. Inc. are the major companies operating in the Global Bladder Cancer Therapeutics and Diagnostics Market.

Which is the fastest growing region in Global Bladder Cancer Therapeutics and Diagnostics Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Bladder Cancer Therapeutics and Diagnostics Market?

In 2025, the North America accounts for the largest market share in Global Bladder Cancer Therapeutics and Diagnostics Market.

What years does this Global Bladder Cancer Therapeutics and Diagnostics Market cover?

The report covers the Global Bladder Cancer Therapeutics and Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Bladder Cancer Therapeutics and Diagnostics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

MEA Pulp and Paper Industry Report

Statistics for the 2025 Global Bladder Cancer Therapeutics and Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Bladder Cancer Therapeutics and Diagnostics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.